Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Dr. Lal PathLabs's share price for the quarter that ended in Jun. 2026 was ₹1646.2. Dr. Lal PathLabs's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 167 Mil. Therefore, Dr. Lal PathLabs's market cap for the quarter that ended in Jun. 2026 was ₹275,363 Mil.
Dr. Lal PathLabs's quarterly market cap
declined
from Dec. 2025 (₹247,548 Mil) to Mar. 2026 (₹219,092 Mil) but then
increased
from Mar. 2026 (₹219,092 Mil) to Jun. 2026 (₹275,363 Mil).
Dr. Lal PathLabs's annual market cap
increased
from Mar. 2024 (₹188,299 Mil) to Mar. 2025 (₹206,651 Mil) and
increased
from Mar. 2025 (₹206,651 Mil) to Mar. 2026 (₹219,092 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Dr. Lal PathLabs's Enterprise Value for Today is ₹315,177 Mil.
Dr. Lal PathLabs (NSE:LALPATHLAB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Dr. Lal PathLabs Market Cap Related Terms
Dr. Lal PathLabs Market Cap Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Market Cap distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Dr. Lal PathLabs's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Market Cap of ₹326,163 Mil as of Aug. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Dr. Lal PathLabs and its competitors. According to the industry distribution chart, Dr. Lal PathLabs ranks #33 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is Dr. Lal PathLabs' Market Cap too high?
Dr. Lal PathLabs' current Market Cap is ₹326,163 Mil. Based on the distribution chart, Dr. Lal PathLabs ranks #33 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #33 out of 217 companies for Market Cap. This places Dr. Lal PathLabs in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 60.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 60.11, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 60.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current Market Cap is ₹326,163 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Market Cap is ₹326,163 Mil. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Market Cap is ₹326,163 Mil as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Market Cap: ₹326,163 Mil
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
